目的 觀察注射用益氣復(fù)脈（凍干）聯(lián)合沙庫(kù)巴曲纈沙坦治療慢性心力衰竭的治療效果。方法 選擇2021年1月—2022年12月河北省退役軍人總醫(yī)院心內(nèi)科、榮軍二科收治的慢性心衰住院患者106例為研究對(duì)象，根據(jù)患者治療方案不同分為對(duì)照組和試驗(yàn)組，每組各53例。對(duì)照組患者給予常規(guī)藥物（袢利尿劑、螺內(nèi)酯、β受體阻滯劑）＋沙庫(kù)巴曲纈沙坦鈉片（口服每次100 mg，每天2次，依據(jù)患者耐受程度，酌情增減劑量，最大劑量為每次200 mg）治療，試驗(yàn)組患者在對(duì)照組基礎(chǔ)上加用注射用益氣復(fù)脈（凍干），注射用益氣復(fù)脈（凍干）5.2 g溶于0.9%氯化鈉注射液250 mL中，靜脈滴注，每天1次。兩組均治療4周。對(duì)比兩組臨床療效，比較治療前后兩組患者氨基端前心鈉肽（NT-proBNP）、左室射血分?jǐn)?shù)（LVEF）、6分鐘步行試驗(yàn)距離（6MWD）、明尼蘇達(dá)州心功能不全生命質(zhì)量量表（MLHFQ）評(píng)分，同時(shí)觀察兩組患者的不良反應(yīng)。結(jié)果 經(jīng)過(guò)4周治療后，試驗(yàn)組總有效率為88.68%，顯著高于對(duì)照組的73.58%（P＜0.05）。治療前兩組患者NT-proBNP、LVEF、6MWD、MLHFQ評(píng)分比較，差異均無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）。治療后，兩組患者NT-proBNP及MLHFQ評(píng)分均較本組治療前顯著降低（P＜0.05），且試驗(yàn)組顯著低于對(duì)照組（P＜0.05）；治療后，兩組患者LVEF和6MWD均較本組治療前顯著增加（P＜0.05），且試驗(yàn)組顯著高于對(duì)照組（P＜0.05）。對(duì)照組發(fā)生1例不良反應(yīng)，試驗(yàn)組未發(fā)生不良反應(yīng)，兩組比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）。結(jié)論 注射用益氣復(fù)脈（凍干）聯(lián)合沙庫(kù)巴曲纈沙坦治療慢性心力衰竭具有較好的臨床療效，且安全性較高。

Objective To observe the therapeutic effect of Yiqi Fumai Lyophilized Injection combined with sacubitril valsartan in treatment of chronic heart failure, and to evaluate the clinical efficacy. Methods A total of 106 hospitalized patients with chronic heart failure admitted to the Department of Cardiology and Department of Rongjun Second of Hebei Veterans General Hospital from January 2021 to December 2022 were selected as the research subjects. They were divided into control group and experimental group based on different treatment plans, with 53 patients in each group. The patients in the control group were given conventional drugs (loop diuretic, spironolactone, and β receptor blocker) ＋Sacubitril Valsartan Sodium Tablets (100 mg orally, twice a day, according to the patient's tolerance, increase or decrease the dose as appropriate, the maximum dose is 200 mg each time). On the basis of the control group, patients in the experimental group added Yiqi Fumai Lyophilized Injection. Each time, 5.2 g of Yiqi Fumai Lyophilized Injection was taken and dissolved in 250 mL of 0.9% Sodium Chloride Injection, intravenous drip, once a day. Both groups were treated for four weeks. The clinical efficacy of the two groups was compared, and the N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), 6-minute walk test distance (6MWD), and Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores of the two groups of patients were compared before and after treatment. At the same time, the adverse reactions of patients in the two groups were observed. Results After four weeks of treatment, the total effective rate of the experimental group was 88.68%, significantly higher than the control group's 73.58% (P＜0.05). Before treatment, there was no statistically significant difference in NT-proBNP, LVEF, 6MWD, and MLHFQ scores between the two groups of patients (P＞0.05). After treatment, the NT-proBNP and MLHFQ scores of both groups of patients were significantly lower than before treatment of same group (P＜0.05), and the experimental group was significantly lower than the control group (P＜0.05). After treatment, LVEF and 6MWD of both groups of patients significantly increased compared to before treatment in same group (P＜0.05), and the experimental group was significantly higher than the control group (P＜0.05). One patient experienced adverse reactions in the control group, while no patient experienced adverse reactions in the experimental group. There was no statistically significant difference between the two groups (P＞0.05). Conclusion The combination of Yiqi Fumai Lyophilized Injection and sacubitril valsartan has good clinical efficacy and high safety in the treatment of chronic heart failure.

邢臺(tái)市重點(diǎn)研發(fā)計(jì)劃自籌項(xiàng)目（2020ZC255）